Systematic Analysis of Chemokines Reveals CCL18 is a Prognostic Biomarker in Glioblastoma

References

• Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22(12Suppl 2):iv1–iv96. doi:10.1093/neuonc/noaa200
   PubMed Web of Science ®Google Scholar
• Wesseling P, Capper D. WHO 2016 classification of gliomas. Neuropathol Appl Neurobiol. 2018;44(2):139–150. doi:10.1111/nan.12432
   PubMed Web of Science ®Google Scholar
• Janjua TI, Rewatkar P, Ahmed-Cox A, et al. Frontiers in the treatment of glioblastoma: past, present and emerging. Adv Drug Deliv Rev. 2021;171:108–138. doi:10.1016/j.addr.2021.01.012
   PubMed Web of Science ®Google Scholar
• Wu W, Klockow JL, Zhang M, et al. Glioblastoma multiforme (GBM): an overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;171:105780. doi:10.1016/j.phrs.2021.105780
   PubMed Web of Science ®Google Scholar
• Iser IC, Pereira MB, Lenz G, Wink MR. The epithelial-to-mesenchymal transition-like process in glioblastoma: an updated systematic review and in silico investigation. Med Res Rev. 2017;37(2):271–313. doi:10.1002/med.21408
   PubMed Web of Science ®Google Scholar
• Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro Oncol. 2009;11(4):341–347. doi:10.1215/15228517-2009-025
   PubMed Web of Science ®Google Scholar
• Gramatzki D, Roth P, Rushing EJ, et al. Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study. Ann Oncol. 2018;29(6):1431–1436. doi:10.1093/annonc/mdy106
   PubMed Web of Science ®Google Scholar
• Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol. 2017;17(9):559–572. doi:10.1038/nri.2017.49
   PubMed Web of Science ®Google Scholar
• Vilgelm AE, Richmond A. Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy. Front Immunol. 2019;10:333. doi:10.3389/fimmu.2019.00333
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. The chemokine superfamily revisited. Immunity. 2012;36(5):705–716. doi:10.1016/j.immuni.2012.05.008
   PubMed Web of Science ®Google Scholar
• Takacs GP, Flores-Toro JA, Harrison JK. Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy. Pharmacol Ther. 2021;222:107790. doi:10.1016/j.pharmthera.2020.107790
   PubMed Web of Science ®Google Scholar
• Urbantat RM, Vajkoczy P, Brandenburg S. Advances in chemokine signaling pathways as therapeutic targets in glioblastoma. Cancers. 2021;13(12):2983. doi:10.3390/cancers13122983
   PubMed Web of Science ®Google Scholar
• Broekman ML, Maas SLN, Abels ER, Mempel TR, Krichevsky AM, Breakefield XO. Multidimensional communication in the microenvirons of glioblastoma. Nat Rev Neurol. 2018;14(8):482–495. doi:10.1038/s41582-018-0025-8
   PubMed Web of Science ®Google Scholar
• Groblewska M, Mroczko B. Pro-and Antiangiogenic factors in gliomas: implications for novel therapeutic possibilities. Int J Mol Sci. 2021;22(11):6126. doi:10.3390/ijms22116126
   PubMed Web of Science ®Google Scholar
• Slettenaar VI, Wilson JL. The chemokine network: a target in cancer biology? Adv Drug Deliv Rev. 2006;58(8):962–974. doi:10.1016/j.addr.2006.03.012
   PubMed Web of Science ®Google Scholar
• Cheng W, Ren X, Zhang C, et al. Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology. 2016;86(24):2226–2234. doi:10.1212/WNL.0000000000002770
   PubMed Web of Science ®Google Scholar
• Zhu Z, Zhang X, Yu Z, et al. Correlation of Tim-3 expression with chemokine levels for predicting the prognosis of patients with glioblastoma. J Neuroimmunol. 2021;355:577575. doi:10.1016/j.jneuroim.2021.577575
   PubMed Web of Science ®Google Scholar
• Dang HH, Ta HDK, Nguyen TTT, et al. Identifying GPSM family members as potential biomarkers in breast cancer: a comprehensive bioinformatics analysis. Biomedicines. 2021;9(9):1144. doi:10.3390/biomedicines9091144
   PubMed Web of Science ®Google Scholar
• Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–795. doi:10.1016/j.immuni.2013.10.003
   PubMed Web of Science ®Google Scholar
• Hanzelmann S, Castelo R, Guinney J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7. doi:10.1186/1471-2105-14-7
   PubMed Web of Science ®Google Scholar
• Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–287. doi:10.1089/omi.2011.0118
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D613. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Bhat AA, Nisar S, Maacha S, et al. Cytokine-chemokine network driven metastasis in esophageal cancer; promising avenue for targeted therapy. Mol Cancer. 2021;20(1):2. doi:10.1186/s12943-020-01294-3
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867. doi:10.1038/nature01322
   PubMed Web of Science ®Google Scholar
• Sallusto F, Baggiolini M. Chemokines and leukocyte traffic. Nat Immunol. 2008;9(9):949–952. doi:10.1038/ni.f.214
   PubMed Web of Science ®Google Scholar
• Letourneur D, Danlos FX, Marabelle A. Chemokine biology on immune checkpoint-targeted therapies. Eur J Cancer. 2020;137:260–271. doi:10.1016/j.ejca.2020.06.009
   PubMed Web of Science ®Google Scholar
• Marcuzzi E, Angioni R, Molon B, Chemokines CB. Chemokine receptors: orchestrating tumor metastasization. Int J Mol Sci. 2018;20(1):96. doi:10.3390/ijms20010096
   PubMed Web of Science ®Google Scholar
• Mollica Poeta V, Massara M, Capucetti A, Chemokines BR. Chemokine receptors: new targets for cancer immunotherapy. Front Immunol. 2019;10:379. doi:10.3389/fimmu.2019.00379
   PubMed Web of Science ®Google Scholar
• Korbecki J, Olbromski M, Dziegiel P. CCL18 in the progression of cancer. Int J Mol Sci. 2020;21(21):7955. doi:10.3390/ijms21217955
   PubMed Web of Science ®Google Scholar
• Luo H, Tao C, Wang P, Li J, Huang K, Zhu X. Development of a prognostic index based on immunogenomic landscape analysis in glioma. Immun Inflamm Dis. 2021;9(2):467–479. doi:10.1002/iid3.407
   PubMed Web of Science ®Google Scholar
• Fazi B, Proserpio C, Galardi S, et al. The expression of the chemokine CXCL14 correlates with several aggressive aspects of glioblastoma and promotes key properties of glioblastoma cells. Int J Mol Sci. 2019;20(10):2496. doi:10.3390/ijms20102496
   PubMed Web of Science ®Google Scholar
• Zhou M, Bracci PM, McCoy LS, et al. Serum macrophage-derived chemokine/CCL22 levels are associated with glioma risk, CD4 T cell lymphopenia and survival time. Int J Cancer. 2015;137(4):826–836. doi:10.1002/ijc.29441
   PubMed Web of Science ®Google Scholar
• Wang J, Toregrosa-Allen S, Elzey BD, et al. Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells. Proc Natl Acad Sci USA. 2021;118(45). doi:10.1073/pnas.2107507118
   Web of Science ®Google Scholar
• Yang H, Zhang Q, Xu M, et al. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis. Mol Cancer. 2020;19(1):41. doi:10.1186/s12943-020-01165-x
   PubMed Web of Science ®Google Scholar
• Szekely B, Bossuyt V, Li X, et al. Immunological differences between primary and metastatic breast cancer. Ann Oncol. 2018;29(11):2232–2239. doi:10.1093/annonc/mdy399
   PubMed Web of Science ®Google Scholar
• Chen J, Yao Y, Gong C, et al. CCL18 from tumor-associated macrophages promotes breast cancer metastasis via PITPNM3. Cancer Cell. 2011;19(4):541–555. doi:10.1016/j.ccr.2011.02.006
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang H, Sun M, et al. CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target. Cancer Commun. 2020;40(2–3):69–80. doi:10.1002/cac2.12010
   PubMed Web of Science ®Google Scholar
• Gutmann DH, Kettenmann H. Microglia/Brain macrophages as central drivers of brain tumor pathobiology. Neuron. 2019;104(3):442–449. doi:10.1016/j.neuron.2019.08.028
   PubMed Web of Science ®Google Scholar
• Jin J, Lin J, Xu A, et al. CCL2: an important mediator between tumor cells and host cells in tumor microenvironment. Front Oncol. 2021;11:722916. doi:10.3389/fonc.2021.722916
   PubMed Web of Science ®Google Scholar